06 February 2013

UAE-based Julphar Inaugurates Manufacturing Facility in Addis Ababa, Ethiopia

- Julphar has invested 170 million birrs in the construction of the plant
- Recruitment of 50 local staff is currently underway

Addis Ababa, Ethiopia - 06 February 2013 –UAE- based Julphar, in conjunction with its local partner, Medtech, today officially inaugurated its first manufacturing facility in Africa in Addis Ababa, Ethiopia. The 40,000 square feet facility is located in the Gerji Jakros region of the Ethiopian capital. Julphar has invested 170 million birrs in the construction of the plant. 

The pharmaceutical market in Africa is significant and growing, with recent estimates of the continent’s market set at between $8-10 billion. In light of this opportunity, Julphar undertook substantial research when developing its Ethiopian facility. The company took great care to examine the therapeutic sectors in the country which are limited or inaccessible in order that the Julphar Ethiopia plant would produce relevant and much needed medicines during its production launch phases. 

Dr Ayman Sahli, Julphar’s CEO, said: ‘Ethiopia’s strategic position within Africa made it an obvious choice for Julphar when it was looking at opportunities to develop a real and tangible presence in this vast continent. We congratulate the Ethiopian Government for the Millenial Development Goals of Ethiopia, particularly in relation to combating disease. We hope to play a significant role in these goals and ultimately in the development of cutting-edge, 21st century healthcare in Ethiopia. The opening of this facility is a clear indication of our commitment to this country and the region.’ 

Dr Mohamed Nuri, CEO of Medtech, commented: ‘Medtech is proud to play a crucial role in the provision of medicines throughout Africa. The opening of this facility will enable us not only to be a vital supplier to the local market but way beyond across the whole continent. We have worked in alignment with the Ethiopian government and other global health organizations in the planning of this facility and we are excited about the impact this will have on local healthcare.’ 

Once fully operational the Julphar plant will produce per annum 25 million bottles of suspension and syrup, 500 million tablets and 200 million capsules. The new plant is equipped with state-of-the-art technology enabling production of Julphar products not only for the local market but also across the African continent. The plant is cGMP compliant and is working towards international accreditation. 

Recruitment of 50 local staff is currently underway across areas of Quality Assurance, Quality Control, Production and Maintenance, Regulatory Affairs and various Administration roles. This will cover the initial stage. Further and ongoing recruitment will occur as the plant becomes fully operational. 

Source: Julphar